Skip to main content
. 2022 Nov 28;68(6):436–452. doi: 10.1177/07067437221140383

Figure 1.

Figure 1.

Depiction of study purpose: to describe how the attitudes and perspectives of PWLE and P/HCPs shape the move towards the clinical implementation of PGx to maximize benefits/mitigate harms within the realities of a publicly funded healthcare system.

PGx = pharmacogenomic; PWLE = people with lived experience; P/HCP = healthcare providers and policy experts.